Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Funding Opportunities

Extramural Grant Review Opportunity Available

Writing a grant? Need another set of eyes?

The Masonic Cancer Center Science Council can appoint individuals to review cancer center faculty members' grant drafts* or grant ideas in a face-to-face setting or in writing, depending on the stage of grant development. The goal is to improve upon members' success in obtaining grants funded by the NCI, ACS, and other national cancer research organizations.

To request a review, contact Elizabeth Fedie, efedie@umn.edu, 624-0653.

*Members should submit their ideas or abstracts and specific aims one cycle (~3-4 months minimum) before the grant is due. We will usually provide feedback within 1 week.

Research Funding Resources
  • News and Notices

    • NOT-OD-16-031
      Updates to NIH & AHRQ Research Performance Progress Reports (RPPR)
      This notice informs the biomedical and health services research community of planned changes to the PHS Research Performance Progress Report (RPPR) instructions for all annual non-competing (Type 5) NIH & AHRQ awards that support research activities.
      These updates to address Rigor and Transparency will take effect for RPPRs due on or after January 25, 2016.
    • Lab Size and Strategic Support of Science: Thoughts on Finding the Right Mix
      Suppose a funding agency happens to have some extra money and needs to decide how to invest it. Should it invest that extra money in a large, highly productive laboratory, so that laboratory can expand a bit more? Or should it invest that extra money in a small to moderate size laboratory? Given our inability to predict the future with great certainty, which approach represents the smarter investment strategy? Jon Lorsch, the director of the National Institute for General Medical Sciences (NIGMS), has posted an interesting video on just this question.
    • Funding Opportunities issue for the NIH Precision Medicine Initiative Cohort Program
      NOT-PM-16-001
      On November 17, the NIH issued the first set of funding opportunities associated with the implementation of the NIH Precision Medicine Initiative ® (PMI) Cohort Program. These included four  funding opportunity announcements for cooperative agreements, and two funding opportunities for Other Transaction awards. Together, the projects these funding opportunities support will build a solid infrastructure for the PMI Cohort Program.
      Links to all funding opportunities supporting the PMI Cohort Program may be accessed through the NIH PMI website's Funding Opportunities page: http://www.nih.gov/precision-medicine-initiative-cohort-program/funding-opportunities.
    • NOT-TR-15-020
      Notice of Corrections to PAR-15-173 "Pre-Application for Collaborative Innovation Award, CTSA Program (X02)"
    • NOT-OD-15-102
      Consideration of Sex as a Biological Variable in NIH-funded Research
      Sex and gender play a role in how health and disease processes differ across individuals, and consideration of these factors in research studies informs the development and testing of preventive and therapeutic interventions in both sexes.  This notice focuses on NIH's expectation that scientists will account for the possible role of sex as a biological variable in vertebrate animal and human studies.
    • NOT-OD-16-004
      NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications 
      The planned changes focus on the following areas:

       

      • Rigor and transparency in research
      • Vertebrate animals
      • Inclusion reporting
      • Data safety monitoring
      • Research training
      • Appendices
      • Font requirements
      • Biosketch clarifications

      Some of the new policies require additional data collection and updates to application forms, with phase one implemented for due dates on or after Jan. 25th, 2016 and phase two implemented for due dates on or after May 25th, 2016.

      Funding Opportunities:

      NOT-OD-15-103
      Enhancing Reproducibility through Rigor and Transparency
      NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.  The key to the successful application of that knowledge toward health outcomes is scientific rigor in conducting biomedical research. 

    • Reminder: Biosketch Requirements for Due Dates On or After May 25, 2015
      Remember, the modified biosketch format is required for applications submitted to NIH for due dates on or after May 25, 2015. Biosketch format pages, instructions, samples and FAQs are available on the Biosketches section of the SF424 (R&R) Forms and Applications page.
    • NIH Fiscal Policy for Grant Awards - FY2015
    • (NOT-OD-15-050)
    • National Institutes of Health
      NIH Increases Salary Cap to $183,300
      (NOT-OD-15-049)
      National Institutes of Health
    •  Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2015
      (NOT-OD-15-048)
      National Institutes of Health
  • External Funding Opportunities
    • Translational Product Development Fund opportunity
      The Clinical and Translational Science Institute announces a funding opportunity for full-time faculty via Translational Product Development Fund (TPDF) request for applications. The TPDF will support health research projects that are intended to lead the development of a novel therapeutic device, diagnostic, or IT product, and will have the potential to be commercialized through the formation of a start-up company or license to an established commercial entity. Letters of intent are due by 5 p.m., Feb. 10.

    • Minnesota Futures Grant Program
      Applications are now being accepted for the Minnesota Futures Grant Program, administered by the Office of the Vice President for Research. The Minnesota Futures program promotes new research and scholarship that address societal challenges by fostering opportunities for researchers to advance new ideas and cross disciplinary boundaries. Letters of Intent are due Feb. 22; full proposals are due March 21. Two grants will be awarded in June.

    • PAR-16-089
      Imaging and Biomarkers for Early Detection of Aggressive Cancer (U01)
      The purpose of this Funding Opportunity Announcement (FOA) is to: (i) invite researchers to submit collaborative research project (U01) applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach, and (ii) establish a Consortium for Imaging and Biomarkers (CIB) to perform collaborative studies, exchange information, share knowledge and leverage common resources.
      Funding: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project.
      Key Dates:
      Letter of Intent due June 11, 2016
      Full application due July 11, 2016

    • PA-16-086
      Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Support)
      The Center for Global Health (CGH) at the National Cancer Institute (NCI) seeks to promote clinical research studies on pediatric Burkitt Lymphoma (BL) in low- and middle-income countries (LMICs) through collaborations and research partnerships between NCI-designated Cancer Centers and partner institutions in LMICs.
      Funding: The combined direct cost budget for the 2-year project period may not exceed $200,000. Application budgets are limited to no more than $100,000 in direct costs in any single year.  These caps are exclusive of consortium/contractual Facilities and Administrative (F&A) costs.
      Key Dates:
      Application due April 15, 2016

    • Ovarian Cancer Investigator-Initiated Research Award
      Supports meritorious basic and clinically oriented research in ovarian cancer. Impact is an important review criterion. Preliminary data are required. Clinical trials are not allowed. Pre-application is required, and then a full application is by invitation only.
      Funding: Maximum funding of $450,000 in direct costs (plus indirect costs) over a period of performance of 3 years.
      Key Dates:
      Full announcement and application instructions will be posted on the Grants.gov website in February 2016.

    • PAR-16-084
      Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
      The National Cancer Institute (NCI) invites P20 planning grant applications for  developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education. A major goal of the NCI P20 partnership programs is to provide support for investigators at ISUPS and Cancer Centers to conduct cancer research pilot projects and cancer research education program. The purpose of the pilot projects and education program is to allow awardees to obtain preliminary data that will lead to competitive grant applications for funding by the NIH/NCI and/or other Federal/Non-Federal agencies.
      Funding: The combined budget of direct costs cannot exceed $275,000 over 4 years.
      Key Dates:
      Application due March 18, 2016

    • PAR-16-049
      Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01)
      This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.
      Funding: $450,000 Direct Costs (excluding consortium F&A costs) per year.
      Key Dates:
      Application due March 17, 2016

    • PA-14-151
      Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
      The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.
      Funding: Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award.
      Key Dates:
      Application due April 8, 2016

    • PA-16-086
      Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Support)
      The Center for Global Health (CGH) at the National Cancer Institute (NCI) seeks to promote clinical research studies on pediatric Burkitt Lymphoma (BL) in low- and middle-income countries (LMICs) through collaborations and research partnerships between NCI-designated Cancer Centers and partner institutions in LMICs.
      Funding: The combined direct cost budget for the 2-year project period may not exceed $200,000. Application budgets are limited to no more than $100,000 in direct costs in any single year.  These caps are exclusive of consortium/contractual Facilities and Administrative (F&A) costs.
      Key Dates:
      Application due April 15, 2016

    • PAR-16-089
      Imaging and Biomarkers for Early Detection of Aggressive Cancer (U01)
      The purpose of this Funding Opportunity Announcement (FOA) is to: (i) invite researchers to submit collaborative research project (U01) applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach, and (ii) establish a Consortium for Imaging and Biomarkers (CIB) to perform collaborative studies, exchange information, share knowledge and leverage common resources.
      Funding: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project.
      Key Dates:
      Letter of Intent due June 11, 2016
      Full application due July 11, 2016

    • Minnesota Futures Grant Program
      In keeping with the OVPR’s strategic plan to address societal challenges, the MN Futures Grant Program is designed to promote research and scholarship beyond existing initiatives through fostering opportunities for researchers to cross disciplinary and professional boundaries. The program is designed to promote in-depth work to enable faculty members to respond collaboratively and boldly to emerging opportunities in interdisciplinary research and scholarship.
      Key Dates:
      Letter of Intent due February 22, 2016
      Full application due March 21, 2016

    • DoD Breast Cancer Research Program
      The Fiscal Year 2016 Defense Appropriations Act provides $120 million to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer.
      Funding: Varies
      Submission due date TBA in February 2016

    • Minnesota Ovarian Cancer Alliance Request for Proposals
      Funding: $70,000 to $100,000
      Deadline: March 1, 2016
      Research proposals may be individual projects or part of a larger research project related to ovarian, primary peritoneal or fallopian tube cancer. Awards will be granted only to projects conducted in the state of Minnesota by Minnesota based researchers. Project funding is available for one year of activity.
      All research proposals will be considered; however, special consideration will be given to:
      proposals which may lead to early detection, better treatment or a cure for ovarian cancer;
      projects that may benefit women living with ovarian cancer today;
      projects that might not otherwise be funded; and
      projects that will result in the development of preliminary data which will enable the researcher to compete for larger national grants. 
    • RFA-HG-16-003, RFA-HG-16-004,
      Characterizing the Functional Elements in the Encyclopedia of DNA Elements (ENCODE) Catalog (UM1)
      These FOAs seek applications to develop and apply generalizable approaches to characterize the role of candidate functional elements identified by the ENCyclopedia Of DNA Elements (ENCODE) in specific biological contexts.  These FOAs solicit activities that include employing one or more assays to characterize the biological function of candidate elements, testing the impact of natural or engineered genetic variants on element function, or using human diseases or biological systems as test cases to evaluate the approaches.
      Funding: Varies
      Key Dates:
      Letter of Intent due February 21, 2016
      Application due March 21, 2016

    • PA-16-083

      Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01)
      This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings.  The overall goal is to support changes to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.
      Funding: Application budgets are not limited but need to reflect the actual needs of the proposed project.
      Key Dates:
      Full application due June 5, 2016

    • PAR-16-084
      Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
      Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for  developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education. A major goal of the NCI P20 partnership programs is to provide support for investigators at ISUPS and Cancer Centers to conduct cancer research pilot projects and cancer research education program. The purpose of the pilot projects and education program is to allow awardees to obtain preliminary data that will lead to competitive grant applications for funding by the NIH/NCI and/or other Federal/Non-Federal agencies.
      Funding: The partner applications, ISUPS and Cancer Center, may request $275,000 in direct costs.  The combined budget of direct costs cannot exceed $275,000.  Up to four years of support.
      Key Dates:
      Full application due March 18, 2016
       
    • PAR-15-104
      Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)
      The Funding Opportunity Announcement (FOA) invites grant applications for targeted infrastructure support of the core functions of Cancer Epidemiology Cohorts (CECs) and methodological research. Through this FOA, the National Cancer Institute (NCI) will support infrastructure and core functions for existing or new CECs. This FOA will also lead to support of core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of the Division of Cancer Control and Population Sciences (DCCPS) at the NCI.
      Funding: The total direct costs for any year may not exceed $2.5M. The maximum project period is 5 years.
      Key Dates:
      Full application due March 11, 2016
       
    • PAR-15-064
      The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor, or sponsor.
      Funding: NIH will contribute $ 100,000 per year toward the salary of the career award recipient, and $ 30,000 per year toward the research development costs of the award recipient, for up to 5 years.
      Key Dates:
      Full application due February 12th for new proposals, and March 12th for renewals/resubmissions/revisions.
       
    • PAR-16-049, PAR-16-051
      Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01)
      ove SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.

      Funding:  $450,000 Direct Costs (excluding consortium F&A costs) per year.  The maximum project period is five years.
      Key Dates:
      Full application due March 17, 2016

      PAR-14-242
      Role of the Microflora in the Etiology of Gastro-Intestinal Cancer  (R01)
      This Funding Opportunity Announcement (FOA) encourages innovative multidisciplinary research projects that will advance our mechanistic understanding of microflora influences on Gastro-Intestinal (GI) carcinogenesis. Recent advances in our knowledge of GI microflora composition and function have generated a flood of new information, technologies, and capabilities that may for the first time allow mechanistic investigations of very complex, networked host/microbiome interactions on a systems wide scale.  This FOA encourages investigators to ingrate this new information into hypothesis-driven studies that can define and validate molecular mechanisms that determine microbe-induced carcinogenic outcomes.
      Funding: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.
      Key Dates:
      Full application due March 3, 2016.

    •  Research Projects to Enhance Applicability of Mammalian Models for Translational Research 
      PAR-16-059, PAR-16-058 
      The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. "Funding: Application budgets are limited to $450,000 direct costs per year.
      Key Dates:
      Application due February 5, 2016

    • Damon Runyon-Sohn Pediatric Cancer Fellowship Award
      The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.
      Funding: This four year award is $50,000 per year for basic scientists, and $60,000 per year for physician scientists.
      Application deadline: March 15, 2016
       
    • Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
      (R21) PA-16-036
      This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought.
      Funding: 2 years, combined direct costs may not exceed $275,000
      Key Dates:
      Application due February 16, 2016
       
    • NCI Small Grants Program for Cancer Research
      (NCI Omnibus R03)  PAR-14-007
      This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), of the National Institutes of Health (NIH) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
      Funding: 2 years, with direct costs limited to $50,000 per year.
      Key Dates:
      Application due February 26th, 2016
       
    • ACS Research Grants
      Research Professor Grants
      The American Cancer Society offers a limited number of grants to mid-career investigators who have made seminal contributions that have changed the direction of basic cancer research. Furthermore, it is expected that these investigators will continue to provide leadership in their research area. Up to two awards are made annually for a five-year term that can be renewed once. The award of up to $80,000 per year (direct costs only) may be used for salary or research project support.
      Funding: Up to $80,000 per year (direct costs only), five-year term.
      Key Dates:
      Letter of Intent due February 1, 2016
      Application due April 1, 2016
       
    • Quantitative Imaging for Evaluation of Response to Cancer Therapies
      PAR-14-116 (U01)
      This Funding Opportunity Announcement (FOA) invites research project - cooperative agreement (U01) applications which are expected to enhance the value of quantitative imaging (QI) in clinical trials for prediction and/or measurement of response to cancer therapies. One avenue for this enhancement is to emphasize the development, optimization and validation of state-of-the-art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials. The second avenue to enhance QI methods is to address the challenges of integrating existing and or new QI methods as required for multicenter phase 3 clinical trials.
      Funding: Direct costs up to $500,000 per year for a maximum of 5 years.
      Key Dates:
      Application due February 5, 2016
    • EvansMDS Strategic Funding Initiatives in Myelodysplastic Syndromes(PDF)
      Edward P. Evans Foundation
      Deadline: Letter of Interest due January 31, 2016

      Discovery Research Grants (DRG)
      Funding: Up to $200,000/year renewal for a second year
      The focus of these awards will be on transformational basic, translational or aspects of clinical research that are directly applicable to the etiology, pathogenesis or treatment of MDS.

      Translational Research Grant (TRG)
      Funding: Up to $500,000/year potentially renewable for a second year
      One grant will be awarded to support a larger scale study that has immediate outcomes for the translation of clinical results and the potential to directly improve MDS patient care. This grant is not intended as the sole funding source of a clinical trial, but rather for the support of ancillary, high impact correlative studies that will supplement the clinical clinical investigation.

      Programmatic Research Grant (PRG)
      Funding: Up to $600,000/year for three years
      This mechanism is designed to stimulate the development of a highly collaborative and interactive group of investigators, either at a single institution or across several institutions, studying high value targets in MDS basic, translational or clinical research. Priority will be given to programs that have the potential to identify new MDS therapies for which the collaborative nature of the research is critical to the proposed aims.

    • Research Professor Awards
      American Cancer Society (ACS)
      The American Cancer Society offers a limited number of grants to provide unique research opportunities to foster maximal productivity in cancer research. These grants provide flexible funding for established investigators in mid-career who have made seminal contributions that have changed the direction of cancer research. Furthermore, it is expected that these investigators will continue to provide leadership in their research area.
      Funding: Two 5-year awards of up to $80,000 made annually.
      Key Dates:
      Letter of Intent - Feb. 1, 2016
      Full Application: April 1, 2016
       
    • Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UG3/UH3)
      RFA-CA-15-024
      This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs.
      Funding: Cooperative agreement, $325,000/yr direct for 2 years (for UG3), $650,000/yr direct for 3 years (for UH3)
      Key Dates:
      Full application: Feb. 9, 2016
       
    • Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)(U54)
      PAR-15-103
      This Funding Opportunity Announcement (FOA) invites cooperative agreement (U54) applications for the implementation of Comprehensive Partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI-designated Cancer Centers (CC). The purpose of this limited competition funding opportunity announcement (FOA) is to continue fostering and supporting intensive collaborations among investigators at ISUPS and CCs in order to develop stronger national cancer programs aimed at understanding the reasons behind the significant cancer disparities and related impacts on these populations.
      Funding: $2.5 million direct/yr for dyads, $3.0 million direct/yr for triads, for a maximum of 5 years
      Full Application: Jan. 28, 2016
       
    • Examination of Survivorship Care Planning Efficacy and Impact (R01 and R21)
      PA-16-012, PA-16-011
      The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes.
      Application due: R01 - Feb. 5th, 2016, R21 – Feb. 16, 2016
       
    • Genomic Data Analysis Network U24 Grants:
      Specialized(RFA-CA-15-020), Visualization(RFA-15-019), and Processing(RFA-CA-15-018) Centers
      This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. The acquired knowledge could facilitate and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. 
      Funding: Specialized is $330,000 direct/year for 5 years, Visualization and Processing are $660,000 direct/year for 5 years
      Full Applications Due: January 27, 2016
       
    • BD Biosciences Cancer Research Grant
      A total of $100,000 worth of research reagents are awarded annually to 10 scientists. Through the grant program, BD Biosciences supports scientists pursuing innovative ideas in cancer research, helping to define the next generation of scientific breakthroughs.
      Funding: $100,000 in research reagents
      Full Application: Jan. 31, 2016
       
    • (NOT-OD-15-044)
      Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)
      (PAR-15-075)
      National Cancer Institute
      Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
      Funding: Standard R01 limits apply
    • NCI Mentored Research Scientist Development Award to Promote Diversity (K01)
      (PAR-15-064)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: $100,000/yr towards salary; $30,000/yr for other expenses
    • NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08)
      (PAR-15-060)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: $100,000/yr towards salary; $30,000/yr for other expenses
    • NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)
      (PAR-15-062)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: $100,000/yr towards salary; $30,000/yr for other expenses
    • National Cancer Institute Program Project Applications (P01)
      (PAR-15-023)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: Varies.
       
    •  Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016 (P50)
      (PAR-14-353)
      National Cancer Institute
      Application Receipt Date(s): January 27, 2016; May 19, 2016; September 22, 2016
      Funding: $2,300,000 total costs/year 
    • Advancing Interventions to Improve Medication Adherence
      PA-14-334 – R01
      PA-14-335 – R21
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: Standard R01 & R21 limit
    • Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)
    • (PAR-14-242)
      National Cancer Institute
      Application Receipt Date(s):  See announcement for dates.
      Funding: Standard R01 limits apply
       
    •  Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)
      (PAR-14-260)
      National Cancer Institute
      Application Receipt Date(s): May 12, 2016, See announcement for additional dates.
      Funding: Standard R01 limits apply.
       
    • Genomic Resource Grants for Community Resource Projects (U41)
      (PAR-14-191)
      National Cancer Institute
      Application Receipt Date(s): January 25, 2016; May 25, 2016; September 25, 2016; January 25, 2017 
      Funding: 5 years of funding.  Application budgets are not limited, but should reflect the needs of the proposed project. 
    • Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)
      (PA-14-114)
      National Cancer Institute
      Funding: Standard R01 limits apply.
      Application Receipt Date(s): Multiple dates, see announcement.
       
    • Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)
      (PAR-14-013)
      National Cancer Institute
      Funding: Standard R21 limits apply
      Deadline: See announcement for dates. 
       
    • Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)
      (PAR-14-116)
      National Cancer Institute
      Funding: $500,000/yr for 5 years
      Application Receipt Date(s): Multiple dates, see announcement 
    • Modeling Social Behavior (R01)
      (PAR-13-374)
      National Cancer Institute
      Deadline: Multiple dates, see announcement.
      Funding: Standard R01 limits apply 
    • Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01)
      (PAR-13-375)
      National Cancer Institute
      Deadline: March 22, 2016
      Funding: Standard R01 limits apply.
    • Pancreatic Cancer Action Network Research Grants Program
      Sponsor: Pancreatic Cancer Action Network and American Association for Cancer Research
      Deadlines: Multiple; see announcement
      Funding: See announcement
      Funding is available for postdoctoral/clinical research fellows as well as for junior and senior independent researchers. The proposed research must be directly relevant to pancreatic cancer. More information about the grants program, including eligibility criteria and application due dates and procedures, is available at http://www.pancan.org/2014grants.
       
    • Research to Characterize and Reduce Stigma to Improve Health

      R01 (PA-13-248)


      R03 (PA-13-247)
      R21 (PA-13-246)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.  Standard cycle dates.
      Funding: Standard limits apply
       
    • Prostate Cancer Research Program (PCRP)
      Sponsor: Department of Defense
      Deadlines: Various; see announcements
      Funding: See announcements
       
    • Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness
      R01 (PA-13-165)
      R15 (PA-13-166)
      R21 (PA-13-167)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: Standard limits apply. See announcements for additional information.
       
    • Bioengineering Research Grants (BRG) (R01)
      (PAR-13-137)
      National Cancer Institute
      Application Deadline: Multiple receipt dates, see announcement. 
      Funding: Standard R01 limits apply
       
    • Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)
      (PAR-13-169)
      National Cancer Institute
      Application Receipt Date(s): Multiple dates, see announcement.
      Funding: standard R01 limits apply 
  • Masonic Cancer Center and University of Minnesota Internal and Extramural Funding Opportunities Requiring Coordination
  • Federal Agencies Funding Cancer-Related Research
  • Non-Federal Agencies Funding Cancer-Related Research
  • Research Funding Directories
    • Catalog of Federal Domestic Assistance (CFDA): CFDA is a database of all federal programs available to state and local governments; federally recognized Indian tribal governments; territories (and possessions) of the United States; domestic public, quasi-public, and private profit and nonprofit organizations and institutions; specialized groups; and individuals.
    • Community of Science Pivot: This funding opportunity search engine provides the world's most comprehensive funding resource, with more than 24,000 records representing nearly 400,000 opportunities ranging from local non-profit funding to federally funded grants.
    • Duke University Funding Opportunities Listing: This is a sortable database of current funding opportunities pulled from various databases. It boasts a user-friendly interface and a comprehensive listing. While the listing is not as comprehensive as other databases in this list, opportunities may be easier to find in this abbreviated format.
    • Foundation Directory Online (requires x.500 login): The premier grantseeking database on the Web, developed by the Foundation Center, a national nonprofit service organization founded over 50 years ago to open up U.S. foundations to public view.
    • Illinois Researcher Information Service (IRIS): A fee-based service, to which the University of Minnesota is a current subscriber. It currently contains over 9,000 active federal and private funding opportunities in the sciences, social sciences, arts, and humanities. In addition to funding opportunities for faculty, the IRIS Database also contains fellowships and scholarships for grad students and undergrads. Users can search IRIS by sponsor, deadline date, keyword, and other criteria. Most IRIS records contain live links to sponsor Web sites, electronic forms, or Electronic Research Administration (eRA) portals. The IRIS Database is updated daily.
    • Sponsored Programs Information Network (SPIN): InfoEd's SPIN is the most widely used funding opportunity database in the world. By aggregating sponsor information in one system, SPIN dramatically cuts search times and substantially increases the likelihood of positive results. Program information is presented in a standard format that allows investigators to readily compare opportunities. This search engine is great for post-doctoral associates looking for funding opportunities.
  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on February 2, 2016